Advertisement
Advertisement
-
Money /

Money News

Related Topics:
Banking & finance
Family offices are increasingly using hedging strategies and derivative instruments to manage portfolio risks, according to a survey. Photo: Sam Tsang
Banking & finance

Hong Kong family offices take long view despite Iran war, HKMA affiliate says

Survey shows family offices expanding risk management while maintaining strong investment exposure to Hong Kong and Asia.

Banking & finance

China investors energise Hong Kong biotech stocks. Is foreign money missing out?

Made in China 2025

China biotech outlicensing tops US$52 billion in first 2 months

Two Sessions 2026

Healthcare investors looking to ‘two sessions’ for clarity on drug pricing

Healthcare and insurance sectors will see policy fine-tuning, ‘moral support’ rather than ‘groundbreaking news’ from Beijing, analysts say.

Staff members dispense medicines at a pharmacy in Wuhan, in central China’s Hubei province, on February 27, 2020. Photo: Xinhua
Staff members dispense medicines at a pharmacy in Wuhan, in central China’s Hubei province, on February 27, 2020. Photo: Xinhua
Made in China 2025

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

Hong Kong stock market

The big cornerstone comeback: what’s driving investors back to Hong Kong IPOs?

After four subdued years, the cornerstone investors that anchor Hong Kong’s IPO market are returning in force, reshaping the deal landscape.

Advertisement
Advertisement
Advertisement
Made in China 2025

After boost from viral dance challenge, Chinese medicine firm’s shares languish

Slumping profits at Shandong Xinhua Pharmaceutical have dragged the shares to about HK$7 in December 2025 from HK$15.62 in December 2022.

The combined daily production capacity of ibuprofen and paracetamol in China surged fourfold to 202 million tablets by late December 2022. Photo: Shutterstock
The combined daily production capacity of ibuprofen and paracetamol in China surged fourfold to 202 million tablets by late December 2022. Photo: Shutterstock
IPO

Shenzhen-listed Unisplendour abandons plan to raise funds in Hong Kong

The Tsinghua Holdings arm, however, will raise US$800 million via a private share placement on Shenzhen exchange.

Made in China 2025

Capital injection: China backs AI drug makers in self-reliance drive

A wave of government-linked investment is boosting Chinese AI drug makers, underscoring Beijing’s drive to build its own biotech ecosystem.

Made in China 2025

Chinese healthcare firms expand overseas to support growing expat community

Privately owned Distinct Healthcare plans to open a clinic in Dubai, while TCM group Gushengtang eyes 50 centres in Southeast Asia.

Distinct Healthcare raised HK$284.53 million from its initial public offering in Hong Kong last week. Photo: Handout
Banking & finance

Mainland China’s investors pour into Hong Kong-listed drug stocks

An index tracking Stock Connect buying of 40 mainland drug firms gains 9 per cent in a week as China’s industry heft grows.

An employee works on a drug production line at a pharmaceutical company in Meishan, China, on January 30, 2024. Photo: NurPhoto via Getty Images
An employee works on a drug production line at a pharmaceutical company in Meishan, China, on January 30, 2024. Photo: NurPhoto via Getty Images
Banking & finance

China slashes wait times for loss-making tech firms seeking refinancing, fundraising

Three of China’s stock exchanges have relaxed fundraising time thresholds on listed tech companies as Beijing pushes for self-reliance.

videocam
Made in China 2025

Fosun Pharma unit licenses lung cancer drug to Eisai in US$1.55 billion deal

The deal comes as Chinese novel drug makers are having more say in how their new medicines are developed with global partners.

IPO

Morgan Stanley sees another record year for Hong Kong IPOs as pipeline hits 450

Mainland China’s issuers will still dominate city’s IPO market, executive says, but US and Southeast Asian companies are also joining in.

Mainland China’s issuers will still dominate city’s IPO market, Morgan Stanley executive says. Photo: Reuters
Banking & finance

Chinese gold, silver investors face gut check amid volatility, fund suspensions

Some retreat to the sidelines as another fund suspends new investments and futures plunge, while others remain determined to buy the dip.

A saleswoman adjusts gold jewellery for sale at a shop in Lianyungang, in China’s eastern Jiangsu province, on December 24, 2025. Photo: AFP
A saleswoman adjusts gold jewellery for sale at a shop in Lianyungang, in China’s eastern Jiangsu province, on December 24, 2025. Photo: AFP
Banking & finance

Global funds, from BlackRock to Temasek, back China’s largest biotech firms

Global institutional investors have built up sizeable positions in firms including Innovent, 3SBio, WuXi Biologics, Jiangsu Hengrui, Akeso and BeOne.

Biomedicine: Industry Trends

Harbour BioMed stake in US drug developer shows Chinese firms’ growing clout

Latest example of Chinese drug maker acquiring equity in overseas partner shows they are becoming true development partners, analysts say.

Advertisement
Advertisement
Advertisement
Made in China 2025

Exclusive | China challenges US in AI drug race, but rivals still reliant on each other

While US biotech firms increase use of Chinese clinical data, Chinese firms need US counterparts for monetisation, investor and scientist says.

Leung Chuen-yan, partner for healthcare investment at Value Partners Group. Photo: Edmond So
Leung Chuen-yan, partner for healthcare investment at Value Partners Group. Photo: Edmond So
Banking & finance

SF Holding, J&T strike US$1 billion deal as Asian e-commerce booms

The agreement will help SF Holding expand its international businesses, according to the Shenzhen-based company.

Made in China 2025

Novartis, SciNeuro deal offers hope for 55 million suffering from Alzheimer’s

SciNeuro’s anti-amyloid programme is one of the firm’s key strategic research and development priorities to target the brain disease.

videocam
Made in China 2025

China’s weight-loss drug war: prices slashed up to 80% as obesity crisis worsens

Foreign, local firms fight for market share as number of overweight or obese adults could top 630 million by 2050, from 400 million in 2021.

There were more than 400 million overweight or obese adults in China in 2021, according to a study. Photo: Getty Images
Banking & finance

TCM firms eye Hong Kong IPOs to fuel global expansion

Over the past year, 34 innovation and technology, life and health science companies set up or expanded their operations in Hong Kong.

A traditional Chinese medicine pharmacy at the Hong Kong Chinese Medicine Hospital in Tseung Kwan O. Photo: Edmond So
A traditional Chinese medicine pharmacy at the Hong Kong Chinese Medicine Hospital in Tseung Kwan O. Photo: Edmond So
Made in China 2025

Chinese biotechs strike a record US$136 billion in out-licensing deals in 2025

Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms last year versus 94 a year earlier.

Made in China 2025

Meow or never: China’s pudgy pets spark race for weight-loss drugs

Fosun and Huadong biotech labs eye feline obesity drugs as owners weigh cuteness against health risks.

Banking & finance

Citic Securities claims top spot in Asia-Pacific investment banking for 2025

Chinese rivals fill out the rest of the top five, while US bank Morgan Stanley comes in sixth.

Citic claimed the crown as the top bookrunner for Asia-Pacific-issued bonds with 6 per cent market share. Photo: Shutterstock Images
Help preserve 120 years of quality journalism.
SUPPORT NOW